Biblio

Export 623 results:
[ Author(Desc)] Title Type Year
Filters: Keyword is Alzheimer Disease  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
R
H. F. M. Rhodius-Meester, Koikkalainen, J., Mattila, J., Teunissen, C. E., Barkhof, F., Lemstra, A. W., Scheltens, P., Lötjönen, J., and van der Flier, W. M., “Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 261-70, 2016.
J. M. Riphagen, van Egroo, M., and Jacobs, H. I. L., “Elevated Norepinephrine Metabolism Gauges Alzheimer's Disease-Related Pathology and Memory Decline.”, J Alzheimers Dis, vol. 80, no. 2, pp. 521-526, 2021.
J. M. Robillard, “The Online Environment: A Key Variable in the Ethical Response to Complementary and Alternative Medicine for Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 11-3, 2016.
M. Rodriguez-Perdigon, Solas, M., and Ramirez, M. Javier, “JNK: A Putative Link Between Insulin Signaling and VGLUT1 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 963-7, 2016.
C. M. Roe, Babulal, G. M., Mishra, S., Gordon, B. A., Stout, S. H., Ott, B. R., Carr, D. B., Ances, B. M., Morris, J. C., and Benzinger, T. L. S., “Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 509-513, 2018.
A. E. Roher, Maarouf, C. L., and Kokjohn, T. A., “Familial Presenilin Mutations and Sporadic Alzheimer's Disease Pathology: Is the Assumption of Biochemical Equivalence Justified?”, J Alzheimers Dis, vol. 50, no. 3, pp. 645-58, 2016.
R. R. Romano, Carter, M. A., Dietrich, M. S., Cowan, R. L., Bruehl, S. P., and Monroe, T. B., “Could Altered Evoked Pain Responsiveness Be a Phenotypic Biomarker for Alzheimer's Disease Risk? A Cross-Sectional Analysis of Cognitively Healthy Individuals.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1227-1233, 2021.
A. F. N. Rosenberger, Hilhorst, R., Coart, E., Barrado, L. García, Naji, F., Rozemuller, A. J. M., van der Flier, W. M., Scheltens, P., Hoozemans, J. J. M., and van der Vies, S. M., “Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 49, no. 4, pp. 927-43, 2016.
J. Paul Ross, Post, S. G., and Scheinfeld, L., “Lucidity in the Deeply Forgetful: A Scoping Review.”, J Alzheimers Dis, vol. 98, no. 1, pp. 3-11, 2024.
E. Rossi, Marrosu, F., and Saba, L., “Music Therapy as a Complementary Treatment in Patients with Dementia Associated to Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 98, no. 1, pp. 33-51, 2024.
D. R. Royall, Palmer, R. F., Matsuoka, T., Kato, Y., Taniguchi, S., Ogawa, M., Fujimoto, H., Okamura, A., Shibata, K., Nakamura, K., Nakaaki, S., Koumi, H., Mimura, M., Fukui, K., and Narumoto, J., “Greater than the Sum of Its Parts: δ can be Constructed from Item Level Data.”, J Alzheimers Dis, vol. 49, no. 2, pp. 571-9, 2016.
L. Rozzini, Lanfranchi, F., Pilotto, A., Catalani, S., Gilberti, M. Enrica, Paganelli, M., Apostoli, P., and Padovani, A., “Serum Non-Ceruloplasmin Non-Albumin Copper Elevation in Mild Cognitive Impairment and Dementia due to Alzheimer's Disease: A Case Control Study.”, J Alzheimers Dis, vol. 61, no. 3, pp. 907-912, 2018.
U. Rüb, Stratmann, K., Heinsen, H., Seidel, K., Bouzrou, M., and Korf, H. - W., “Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.”, J Alzheimers Dis, vol. 57, no. 3, pp. 683-696, 2017.
U. Rüb, Stratmann, K., Heinsen, H., Del Turco, D., Ghebremedhin, E., Seidel, K., Dunnen, Wden, and Korf, H. - W., “Hierarchical Distribution of the Tau Cytoskeletal Pathology in the Thalamus of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 49, no. 4, pp. 905-15, 2016.
J. D. 'Arcy Rudge, “The Lipid Invasion Model: Growing Evidence for This New Explanation of Alzheimer's Disease.”, J Alzheimers Dis, vol. 94, no. 2, pp. 457-470, 2023.
A. Rustamzadeh, Tafakhori, A., Ariaei, A., Heydari, M., Shah-Abadi, M. Ebrahimi, and Seif, F., “Targeting Caspases 3/6 and Cathepsins L/B May Decrease Laminopathy-Induced Apoptosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 101, no. 1, pp. 211-221, 2024.
Z. Rusznák, Kim, W. Scott, Hsiao, J. - H. T., Halliday, G. M., Paxinos, G., and Fu, Y. H., “Early in vivo Effects of the Human Mutant Amyloid-β Protein Precursor (hAβPPSwInd) on the Mouse Olfactory Bulb.”, J Alzheimers Dis, vol. 49, no. 2, pp. 443-57, 2016.
S. G. Ryman, Yutsis, M., Tian, L., Henderson, V. W., Montine, T. J., Salmon, D. P., Galasko, D., and Poston, K. L., “Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 80, no. 3, pp. 1243-1256, 2021.
S
L. Saarelainen, Taipale, H., Koponen, M., Tanskanen, A., Tolppanen, A. - M., Tiihonen, J., and Hartikainen, S., “The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 3, pp. 809-18, 2016.
P. Sachdeva, Narayanan, K. Badri, Sinha, J. Kumar, Gupta, S., Ghosh, S., Singh, K. Kumar, Bhaskar, R., Almutary, A. G., Zothantluanga, J. H., Kotta, K. Kumar, Nelson, V. Kumar, Paiva-Santos, A. Cláudia, Abomughaid, M. Mohammad, Kamal, M., Iqbal, D., ALHarbi, M. Hamoud, ALMutairi, A. Aedh, Dewanjee, S., Nuli, M. Vamsi, Vippamakula, S., Jha, S. Kumar, Ojha, S., and Jha, N. Kumar, “Recent Advances in Drug Delivery Systems Targeting Insulin Signalling for the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 98, no. 4, pp. 1169-1179, 2024.
M. Safieh, Liraz, O., Ovadia, M., and Michaelson, D., “The Role of Impaired Receptor Trafficking in Mediating the Pathological Effects of APOE4 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 2, pp. 753-775, 2024.
T. Saksida, Koprivica, I., Vujičić, M., Stošić-Grujičić, S., Perović, M., Kanazir, S., and Stojanović, I., “Impaired IL-17 Production in Gut-Residing Immune Cells of 5xFAD Mice with Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 61, no. 2, pp. 619-630, 2018.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., “Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
S. Salmerón, Huedo, I., López-Utiel, M., Soler-Moratalla, I., Flores-Ruano, T., Fernández-Sánchez, M., Noguerón, A., Doody, R. S., and Abizanda, P., “Validation of the Spanish version of the Baylor Profound Mental Status Examination.”, J Alzheimers Dis, vol. 49, no. 1, pp. 73-8, 2016.
N. Samudra, Ranasinghe, K., Kirsch, H., Rankin, K., and Miller, B., “Etiology and Clinical Significance of Network Hyperexcitability in Alzheimer's Disease: Unanswered Questions and Next Steps.”, J Alzheimers Dis, vol. 92, no. 1, pp. 13-27, 2023.

Pages